OncoMatch/Clinical Trials/NCT07106762
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Is NCT07106762 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Iza-bren and Cisplatin for urothelial cancer.
Treatment: Iza-bren · Cisplatin · Gemcitabine · Carboplatin — A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Urothelial Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — locally advanced or metastatic
Anti-PD-(L)1-experienced (in locally advanced or metastatic setting), either in combination with or sequential to another systemic therapy.
Cannot have received: platinum-based chemotherapy
Exception: allowed if >12 months since last exposure
must not have platinum-based chemotherapy exposure within 12 months
Cannot have received: antibody-drug conjugate targeting EGFR
must not have prior ADC therapy targeting EGFR
Cannot have received: antibody-drug conjugate targeting HER3
must not have prior ADC therapy targeting HER3
Cannot have received: topoisomerase 1 inhibitor
must not have prior therapy with topoisomerase 1 inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0167 · Gilbert, Arizona
- Local Institution - 0162 · Fullerton, California
- Local Institution - 0252 · Palo Alto, California
- Local Institution - 0163 · Sacramento, California
- Local Institution - 0139 · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07106762 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior platinum-based chemotherapy, antibody-drug conjugate targeting EGFR, antibody-drug conjugate targeting HER3 disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages